Elanco Animal Health Inc (XTER:5EA) Stock Price, Trades & News

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.11
Equity-to-Asset	0.49
Debt-to-Equity	0.61
Debt-to-EBITDA	5.46
Interest Coverage	1.27
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	1.48	Distress Grey Safe
Beneish M-Score	-2.59	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

5/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	1.7
	3-Year EBITDA Growth Rate	-7.9
	3-Year EPS without NRI Growth Rate	-5.4
	3-Year FCF Growth Rate	1.4
	3-Year Book Growth Rate	-5
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	14.09
	Future 3-5Y Total Revenue Growth Rate Estimate	5.88

Momentum Rank

10/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	39.35
	9-Day RSI	38.86
	14-Day RSI	42.07
	3-1 Month Momentum %	11.43
	6-1 Month Momentum %	10.6
	12-1 Month Momentum %	10.6

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.16
	Quick Ratio	1.12
	Cash Ratio	0.26
	Days Inventory	279.65
	Days Sales Outstanding	71.76
	Days Payable	59.42

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-1.6
	Shareholder Yield %	5.12

Profitability Rank

4/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	55.06
	Operating Margin %	6.13
	Net Margin %	-4.95
	EBITDA Margin %	14.94
	FCF Margin %	6.43
	OCF Margin %	11.78
	ROE %	-3.68
	ROA %	-1.81
	ROIC %	2.4
	3-Year ROIIC %	5.71
	ROC (Joel Greenblatt) %	1.41
	ROCE %	0.34
	Years of Profitability over Past 10-Year	3
	Moat Score	5
	Tariff Resilience Score	6

GF Value Rank

3/10

	Name	Current	Vs Industry		Vs History
	Forward PE Ratio	22.97
	PE Ratio without NRI	26.36
	Price-to-Owner-Earnings	37.06
	PS Ratio	2.64
	PB Ratio	1.98
	Price-to-Free-Cash-Flow	40.74
	Price-to-Operating-Cash-Flow	22.31
	EV-to-EBIT	411.59
	EV-to-Forward-EBIT	25.84
	EV-to-EBITDA	22.52
	EV-to-Forward-EBITDA	15.69
	EV-to-Revenue	3.36
	EV-to-Forward-Revenue	3.24
	EV-to-FCF	52.27
	Price-to-GF-Value	1.66
	Price-to-Projected-FCF	1.95
	Earnings Yield (Greenblatt) %	0.24
	FCF Yield %	2.44

Financials (Next Earnings Date:2026-08-05)

Annual Quarterly TTM

XTER:5EA's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Elanco Animal Health Inc Executives

Details

GF Value™: €12.11

XTER:5EA

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with 5EA. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	4,207.562
	EPS (TTM) (€)	-0.521
	Beta	-
	3-Year Sharpe Ratio	-0.07
	3-Year Sortino Ratio	-0.11
	Volatility %	11.19
	14-Day RSI	42.07
	14-Day ATR (€)	0.331275
	20-Day SMA (€)	20.92565
	12-1 Month Momentum %	10.6
	52-Week Range (€)	17.958 - 23.085
	Shares Outstanding (Mil)	497.17

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Elanco Animal Health Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Elanco Animal Health Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-11-05 08:00	In 109 days
Third quarter earnings results for 2026	2026-11-05	In 108 days
Second quarter earnings conference call for 2026	2026-08-05 08:00	In 17 days
Second quarter earnings results for 2026	2026-08-05	In 16 days
William Blair 46th Annual Growth Stock Conference	2026-06-02 15:20	20.06 (+0.00%)
Guidance call for 2026	2026-05-27 08:00	20.06 (+0.00%)
General meeting for 2026	2026-05-21 08:00	20.06 (+0.00%)
First quarter earnings conference call for 2026	2026-05-06 08:00	20.06 (+0.00%)
First quarter earnings results for 2026	2026-05-06	20.06 (+0.00%)
KeyBanc Capital Markets Healthcare Forum	2026-03-17 09:00	20.06 (+0.00%)

Show

Entries

Elanco Animal Health Inc Frequently Asked Questions

What is Elanco Animal Health Inc(XTER:5EA)'s stock price today?

The current price of XTER:5EA is €20.06. The 52 week high of XTER:5EA is €23.09 and 52 week low is €17.96.

When is next earnings date of Elanco Animal Health Inc(XTER:5EA)?

The next earnings date of Elanco Animal Health Inc(XTER:5EA) is 2026-08-05.

Does Elanco Animal Health Inc(XTER:5EA) pay dividends? If so, how much?

Elanco Animal Health Inc(XTER:5EA) does not pay dividend.

Press Release

	Subject	Date
	Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement	2026-07-08
	Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health	2026-06-18
	Elanco Announces USDA Approval of TruCan™ Ultra Lyme-L4, the First and Only 1/2 mL Combination Vaccine for Lyme and Leptospirosis for Dogs	2026-06-15
	Elanco Animal Health Commits to Supporting U.S. Livestock Producers and Pet Owners in Fight Against New World Screwworm	2026-06-04
	New Research Reveals Pet Spending as a "Protected Budget Item" for Owners, Fueling Industry Resilience	2026-06-03
	Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market	2026-05-18
	Elanco to Participate in Upcoming Investor Conferences	2026-05-14
	/C O R R E C T I O N -- Elanco Animal Health/	2026-04-28
	Elanco's Negasunt™ Powder (Coumaphos, Propoxur, Sulfanilamide Topical Powder) and Tanidil™ (Coumaphos, Propoxur) Receive Emergency Authorization for Use Against New World Screwworm in Livestock	2026-04-27
	Elanco Confirms Date and Conference Call for First Quarter 2026 Financial Results Announcement	2026-04-16

10/Page

Articles on Elanco Animal Health Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.